PORTAGE, Mich., March 4, 2025 /PRNewswire/ -- Stryker (NYSE:SYK), a global leader in medical technologies, announced the launch of its Steri-Shield 8 personal protection system, the latest in its personal protective equipment (PPE). Steri-Shield 8 was designed through years of research, testing and collaboration with real-world users.
"Over the last 30 years, we have relentlessly innovated our personal protection system to address the needs of today's professionals and prioritize the safety and well-being of care team members and patients," said Bill Scott, vice president and general manager of Stryker's Orthopaedic Instruments business. "As the personal protection system leader in the market, we're pleased to introduce the Steri-Shield 8 system to further enhance protection and wearability."
The Steri-Shield 8 personal protection system includes a helmet with three points of contact for a customizable fit, a sleeker battery, a more efficient charging station and three toga styles.
Key features include:
For more information, visit: https://www.stryker.com/us/en/orthopaedic-instruments/products/steri-shield-8.html
About Stryker
Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 million patients annually. More information is available at www.stryker.com.
*Stryker internal data
Media Contact:
Beth Sizemore
Sr. Director, Strategic Communications, Instruments
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$394.22 |
Daily Change: | 9.39 2.44 |
Daily Volume: | 868,660 |
Market Cap: | US$150.710B |
July 31, 2025 May 01, 2025 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load